Rockwell Medical, Inc. (DE) - RMTI STOCK NEWS

Rockwell Medical, a biopharmaceutical company focused on iron deficiency treatments, will present at the 2021 LD Micro Invitational XI on June 10 at 2:30 PM EDT. The virtual conference will be accessible via a live webcast on their website. Rockwell Medical is known for its innovative Ferric Pyrophosphate Citrate technology and has two FDA-approved therapies for hemodialysis patients. The company aims to expand its FPC platform for treating iron deficiency anemia in various settings.

Rockwell Medical (Nasdaq: RMTI) reported a 2021 Q1 revenue of $15.5 million, down from $15.9 million YoY. The net loss was $7.8 million, slightly improved from $8.0 million in Q1 2020. Key developments include FDA acceptance for its Home Infusion FPC program, aiming for Phase 2 trial initiation in late 2021, and marketing approval for Triferic AVNU™ in Canada. The company ended Q1 with $46.1 million in cash and expects Triferic AVNU to launch commercially in Canada in 2022.

Rockwell Medical, Inc. (Nasdaq: RMTI) announced a conference call on May 17, 2021, at 4:30 p.m. ET to discuss its financial results for Q1 2021 and recent operational updates. Interested parties can join by calling (877) 383-7438 or (678) 894-3975, using conference ID 7870946, or via a live webcast available on their investor website. The call will feature insights into the company's innovative parenteral iron technology, Ferric Pyrophosphate Citrate, aimed at transforming iron deficiency treatments. Archived webcasts will be available for 30 days post-event.

Rockwell Medical, Inc. (Nasdaq: RMTI) announced that Triferic AVNU received marketing approval from Health Canada for maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The company anticipates Triferic AVNU's commercial availability in Canada in 2022, which could benefit over 20,000 Canadians undergoing dialysis. This marks the first international approval for their intravenous therapy and is crucial for expanding their market presence.

Rockwell Medical (Nasdaq: RMTI) presented data at the NHIA 2021 Annual Conference, showcasing the feasibility of managing iron deficiency anemia (IDA) in home parenteral nutrition patients. The study revealed that over 50% of these patients experience IDA, highlighting an unmet clinical need. Despite a strong preference for intravenous (IV) iron among healthcare providers, oral iron remains the first-line therapy. Rockwell Medical plans to initiate a randomized clinical trial to evaluate the safety and efficacy of parenteral iron treatment delivered at home, based on positive prior safety data from FPC.

Rockwell Medical reported its 2020 financial results, achieving revenues of $62.2 million, with a cash balance of $58.7 million at year-end. The company highlighted growth in its dialysis business, particularly through Triferic, which generated approximately $1.1 million in revenue. Cost savings of $296,000 were noted from Triferic's use in clinics. The company is focusing on expanding its FPC technology for treating iron deficiency anemia and acute heart failure. They appointed several industry leaders to their board to strengthen management.

Rockwell Medical, Inc. (Nasdaq: RMTI) will host a conference call on March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the year ended December 31, 2020, along with operational highlights. Interested parties can join by calling (877) 383-7438 or (678) 894-3975, and a live webcast will be available on their investor website. The company focuses on treating iron deficiency and anemia management, particularly in hemodialysis patients. Its FDA-approved therapies, Triferic Dialysate and Triferic AVNU, aim to improve outcomes for this patient demographic.

Rockwell Medical (Nasdaq: RMTI) announced that its executive team will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 1:30 p.m. Eastern Time. The pre-recorded presentation will be accessible in the ‘Investors’ section of the Company’s website. Rockwell Medical focuses on transforming iron deficiency and anemia management, particularly in end-stage kidney disease, with FDA-approved treatments Triferic and Triferic AVNU, which uniquely maintain hemoglobin levels in hemodialysis patients.

Rockwell Medical (Nasdaq: RMTI) announced the availability of Triferic AVNU, an FDA-approved IV formulation for iron replacement in hemodialysis patients with chronic kidney disease. Approved in March 2020, Triferic AVNU enhances treatment options for patients by allowing greater flexibility in iron maintenance therapy. This product is distributed via Rockwell Medical and Metro Medical, targeting U.S. dialysis clinics. Triferic and Triferic AVNU are the only approved therapies in the U.S. for maintaining hemoglobin in hemodialysis patients, addressing significant medical needs.